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ADSTí' :CT 
Chronic asthmatics norrally respond to oral 
corticosteroid therapy with an increase in their ventilatory 
function. However, Grant and his co- workers identified a small 
proportion of severe chronic asthmatics who did not improve 
their ventilatory function when given oral corticosteroid. 
These patients were termed "corticosteroid resistant ". This 
thesis describes the in vitro and in vivo effects of the 
corticosteroid, Ilethylprednisolone (INS), on monocytes and T- 
cells from Corticosteroid Sensitive (CS) and Corticosteroid 
Resistant (CR) asthmatics. 
In vitro colony formation by mononuclear cells (HNC) from 
CS- gsthmatics was found to be significantly more inhibited by 
to i.í MPS than was colony formation by MNC from CR 
asthmatics. This in vitro assay of corticosteroid sensitivity 
was subsequently used diagnostically to discriuina_te between CS 
and CR asthmatics. It was demonstrated that the 
unresponsiveness of HNC from CR asthmatics to MPS in vitro was 
attributable to the monocytes from these patients. Defects in 
the corticosteroid sensitivity of T- cells, eosinophils and 
polyL_orphs were also observed in vivo and in vitro ; their 
relatiónship to the monocyte defect was not clarified. 
Monocytes are thought to affect the Type 1 
hypersensitivity reaction seen in asthma by the production of 
many factors. Two of these factors are of particular relevance 
to this thesis: lipomodulin, which inhibits prostanoid 
synthesis and is induced by corticosteroid and Interleukin 1, 
which supports T- lymphocyte proliferation and is inhibited by 
corticosteroid. There is therefore reason to believe that the 
defect in corticosteroid responsiveness demonstrated in 
monocytes from CR asthmatics in vitro could reduce the 
therapeutic efficacy of these drugs in patients with this 
condition. 
If this is so, these findings emphasise the importance of 
the actions of corticosteroid on monocyte function in the 
commoner CS asthma. Further investigation of this phenomenon 
may have wider implications for other developmental and 
pathological processes. 
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CORTICOSTEROID RESISTANCE IN CHRONIC ASTHMA 
INTRODUCTION 
Corticosteroids are of considerable value in the treatment 
of acute and chronic asthma [Crompton 1982]. However, the 
mechanisms by which corticosteroids act in asthma are not fully 
understood. There are several possibilities which include the 
action of corticosteroid on the production of mediators by mast 
cells, on IgE production by plasma cells, on the regulation of 
these by monocytes and T -cells and on other leucocytes 
including neutrophils and eosinophils [Cupps and Fauci 1982]. 
This thesis describes the effects that the corticosteroid, 
methylprednisolone (MPS), have on monocyte and T -cell function 
in vivo and in vitro. It exploits the recent identification of 
chronic asthmatics who are resistant to the therapeutic effects 
of corticosteroids [Carmichael et al. 1981]. By demonstrating 
that corticosteroid resistance is a property of the monocyte of 
such patients, this study emphasises the effects of 
corticosteroid on monocytes in the commoner corticosteroid 
sensitive asthmatics. This is of particular interest in view of 
much recent evidence that monocytes play a central role in the 
regulation of immunoreactivity and in the inflammatory 
response. Furthermore, it has been shown recently that these 
monocyte functions are influenced by corticosteroids (See 
Diagram). 

































































































































































































































































































































































































































































































Accordingly this introduction will discuss the following 
topics: the pathogenesis of asthma, the atopic production of 
IgE, corticosteroid effects on the inflammatory and immune 
response in general and current theories of the mode of action 
of corticosteroids in asthma and finally the phenomenon of 
corticosteroid resistant asthma. 
The Pathogenesis of Asthma 
In 1921 Prausnitz and Kustner demonstrated the presence of 
an antibody like factor, termed "reagin ", in the serum of 
atopic subjects. They went on to demonstrate the passive 
transfer of a hypersensitivity reaction by subcutaneous 
injection of the atopic patient's serum into a non -atopic 
recipient. A typical local immediate type hypersensitivity 
reaction was elicited when the allergen was subsequently 
applied to the injection site. Since that time the structure 
and function of "reagin ",'now known to be Immunoglobulin E 
(IgE), is more fully understood [Taussig 1979]. 
IgE is normally produced in small amounts in response to 
parasite infestation and particle bound antigens. However the 
major significance of IgE is as a mediator of immediate type 1 
hypersensitivity reactions, including those seen in allergic 
disorders. In atopic individuals IgE is produced in response to 
ubiquitous antigens otherwise known as allergens. The IgE is 
bound via its Fc portion to specific receptors on basophils in 
the peripheral blood and more significantly to mast cells in 
tissues such as skin and various mucosae. Subsequent 
combination of the allergen with the cell bound IgE results in 
basophil or mast cell degranulation. The mast cell releases 
histamine, platelet activating factor, leukotrienes, eosinophil 
chemotactic factor, prostaglandins and other mediators of the 
inflammatory reaction characteristic of immediate type 
hypersensitivity. This release of inflammatory mediators may 
also be stimulated by non -immununological stimuli such as 
stress and temperature change. The result of mast cell 
degranulation is bronchospasm and laryngeal oedema. The 
hypersensitivity reaction may in turn be moderated by 
substances released from eosinophils. 
IgE Production in the Atopic Individual 
One major cause of asthma is a disorder in regulation of 
IgE production. It has been noted that atopic individuals do 
produce high levels of IgE in response to the allergen to which 
they are sensitised [Orgel 1975; Rachelefsky 1976]. 
There is a clear genetic predisposition to the formation 
of IgE in response to allergens [Taussig 1979]. Family studies 
demonstrated the association of atopic production of IgE with 
the HLA -A7 haplotype. Statistical analysis of such data 
indicates that the control of IgE responsiveness to a specific 
allergen is itself determined by a single Ir gene. The Ir gene 
is intimately associated with genes controlling the expression 
of the HLA -A7 antigen. 
The cellular requirements for normal IgE production are 
specific IgE producing plasma cells, B- Memory Lymphocytes , 
regulator T- Lymphocytes and monocytes [Ishizaka 1976]. The 
interaction between these subpopulations of lymphocytes and 
monocytes results in the controlled production of IgE in 
response to specific stimuli. 
Regulation of IgE production by T -cells (including T- 
inducer and T- cytotoxic /suppressor cells) is mediated by 
soluble factors known as IgE binding factors [Ishizaka 1982]. 
Ishizaka and his coworkers isolated a potentiating factor which 
specifically promoted IgE production in their test in vitro 
system [Suemura et al. 1980]. They have also isolated a 
suppressor factor which reduces IgE production [Hirashima 
1980]. Both these factors have a high affinity for IgE and 
differ only in their carbohydrate moiety. The control of the 
production of IgE potentiating and suppressor factors is 
currently being investigated. 
Uede et al. have identified a protein capable of 
modulating the biologic activities of the IgE binding factors 
[Uede et al. 1983]. The factor, termed glycosylation- inhibiting 
factor (GIF), is a lymphokine derived from 0X8+ 
cytotoxic /suppressor T- cells. GIF is capable of promoting the 
selective formation of IgE suppressive factors by T- 
lymphocytes. GIF is currently thought to be a fragment of 
phosphorylated lipomodulin. This is of particular relevance to 
this thesis as lipomodulin synthesis, at least by monocytes and 
neutrophils, is known to be induced by corticosteroid as will 
be discussed later. 
There is some direct evidence that soluble factors from T- 
cells may be involved in the abnormal production of IgE. For 
example it has been shown that T -cells isolated from patients 
with hyper IgE states (hyperIgEaemia, atopic states and acute 
graft versus host disease) release a factor which induces 
synthesis of IgE by plasma cells [Saryan et al. 1983]. This 
factor was not produced by T -cells from controls. 
The notion that atopic states result from disordered 
immunoregulation is supported by much indirect evidence. For 
example cell mediated immunity is reduced in asthmatics which 
results in their propensity to develop viral and fungal 
infections [Gupta 1980]. Strannegard (1978), Brasher (1977), 
Tornita et al. (1982), Hsieh (1980), Gupta and Good (1981) all 
noted abnormalities in T- cell composition and function in 
atopic individuals, in particular in asthmatics, as compared 
with non -atopic individuals. These defects included an overall 
decrease in T -cell numbers, T -cell responsiveness to mitogens, 
active E- rosette formation and non- specific T- suppressor 
activity. A decrease in T -cells with receptors for IgG has also 
been noted in chronic asthmatics. In addition to these defects 
in T -cell function, Geha demonstrated that patients with 
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hyperlgEaemia and atopic states had reduced numbers of 
circulating T- cytotoxic /suppressor cells in their peripheral 
blood [Geha et al. 1981 ;0'Driscoll and Kay 1982]. 
Thus it is possible that atopy arises as a result of 
abnormal T- cell function [Jarret 1977; Stannegard 1979]. 
Jarret goes on to propose that a T- suppressor cell /T- helper 
cell imbalance may result in the excess stimulation of B -cell 
production of IgE that is seen in asthma. 
Corticosteroid Mediated Immunoregulation in Man 
Corticosteroids have widespread effects on the immune and 
inflammatory responses in man and these are extensively 
exploited therapeutically [Cupps and Fauci 1982]. These effects 
involve the depression of the number and function of 
circulating eosinophils, basophils and monocytes [Dunsky 1979]. 
The peak effect occurs 8 hours after the oral administration of 
corticosteroid and recovery occurs during the following 72 
hours. The effects of corticosteroids on the control of the 
immune response are more complex and involve profound actions 
on monocyte and T- lymphocytes. 
1. Effects on Monocytes. 
Monocytes play an important role in the induction and 
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regulation of immune reactivity. Monocytes also contribute to 
and regulate the release of inflammatory mediators. 
Low concentrations of corticosteroids (10 -8M to 10 -9 
M MPS) inhibit Interleukin 1 (IL 1) production by monocytes 
[Smith and Ruscetti 1981; Snyder and Unanue 1982]. 
Corticosteroids may also inhibit T- lymphocyte responsiveness to 
IL 1 [Palacios 1982]. Corticosteroids therefore inhibit the 
subsequent activation of T- cells by IL 1 and the production of 
Interleukin 2 (IL 2) by these activated T- cells. The inhibition 
of IL 1 production may account for the inhibitory effects that 
low concentrations of corticosteroids are seen to have on 
Phytohaemagglutinin (PHA) induced T -cell blastogenesis and 
colony formation in vitro [Krajewski and Wyllie 1981]. 
In contrast corticosteroids promote the production of the 
protein lipomodulin by monocytes and also neutrophils [Flower 
and Blackwell 1979]. The majority of lipomodulin is 
phosphorylated and then cleaved to form smaller molecules. One 
such fragment of phosphorylated lipomodulin termed 
"macrocortin" has anti- phospholipase A2 activity and 
consequently modifies prostanoid synthesis [Hirata 1982 ;Flower 
and Blackwell 1979]. Macrocortin is also capable of modulating 
the biologic activities of IgE binding factors through its 
postulated action as Glycosylation Inhibiting factor (GIF). GIF 
promotes the selective biosynthesis of IgE suppressor factor by 
specific regulator T- cells. Corticosteroids therefore promote 
lipomodulin synthesis by monocytes and neutrophils and thereby 
modify the synthesis of the inflammatory mediators and 
selectively suppress the production of IgE. 
Pharmacologic doses of corticosteroids have a variety of 
other less specific effects on monocyte function, the 
mechanisms of which are as yet unknown. These include 
inhibition of chemotaxis, suppression of the bactericidal and 
fungicidal actions and inhibition of la expression by monocytes 
[Rinehart et al. 1974; Baugren and Anderson 1977 ;Snyder and 
Unanue 1982]. The function of the monocyte in mixed leucocyte 
reactions is particularly sensitive to pharmacologic doses of 
corticosteroids in vivo and in vitro [Katz and Fauci 1979]. 
2. Effects on T- Lymphocytes. 
Corticosteroids have profound effects on T- Lymphocytes in 
vivo and in vitro. These 'effects include an alteration in T- 
cell subpopulations and their function [Cupps and Fauci 1982]. 
Pharmacologic doses of corticosteroids cause a decrease in 
overall T -cell numbers. The maximal effect occurs six hours 
after the administration of a single dose of the drug with 
return to normality within 24 hours [Cupps and Fauci 1982]. 
Haynes and Fauci noted a preferential depletion of T -cells 
bearing Fc receptors for IgM (Tm cells) with a subsequent rise 
in the proportion of T -cells with receptors for IgG (Tg cells) 
- 10 - 
during the six hours following the corticosteroid dose [Haynes 
and Fauci 1978]. The Tg /Tm ratio returns to normal within 24 
hours. It has been suggested that Tm cells have a predominantly 
helper cell role to play in immune regulation whereas Tg cells 
suppress the immune response [Moretta et al. 1976]. Recent work 
that utilised more accurate markers of T -cell subsets 
demonstrated that a single 100mg. dose of prednisolone caused 
preferential depletion of T- inducer cells as compared to T- 
cytotoxic/suppressor cells within 6 hours of the 
administration of the drug [Dupont et al. 1983]. 
Corticosteroids at low doses inhibit lectin induced T -cell 
blastogenesis in vitro. This is thought to be in part due to 
inhibition of IL 1 production by monocytes as described above. 
However, Cupps and Fauci suggest that corticosteroid may also 
directly suppress T -cell responsiveness to IL 1 and thereby 
inhibit IL 2 production by activated T -cells [Krajewski and 
Wyllie 1981]. Corticosteroids have a variety of other effects 
on T -cell function in vitro including inhibition of the 
allogenic and autologous mixed leucocyte reactions and 
inhibition of T -cell mediated cytotoxicity and 
immunosuppression [Katz and Fauci 1979, Onsrud and Thornsby 
1981, Parillo and Fauci 1978, Clarke et al. 1977, Haynes and 
Fauci 1979, Galamud et al. 1981]. 
Recently Uede demonstrated that 0X8+ suppressor /cytotoxic 
splenic T- lymphocytes treated with Freund's adjuvant release a 
lymphokine which is identical in its action to the GIF that is 
released by monocytes and neutrophils in the presence of 
corticosteroid as described above [Uede et al. 1983]. 
Corticosteroid may soon be shown to promote the production of 
GIF by T- cells. 
It is clear from this discussion that corticosteroids have 
significant effects on monocyte and T -cell function which may 
be relevant to the mechanism of their therapeutic action in 
asthma: these effects include suppression of IgE production by 
plasma cells and the inhibition of the production of the 
prostanoids. Both of these effects are mediated by the monocyte 
products lipomodulin and macrocortin. Of particular relevance 
to this thesis is corticosteroid mediated inhibition of IL i 
production by monocytes and the consequent inhibition of 
monocyte dependent T -cell activation and proliferation in 
vitro. 
Corticosteroid Resistance in Asthma 
Corticosteroids are amongst the most important drugs used 
in the treatment of acute and chronic asthma. Inhalant 
corticosteroids are a major component of maintenance therapy 
for chronic asthma whereas systemic corticosteroid therapy is 
administered in acute asthma [Crompton 1982]. 
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Severe chronic asthmatics normally respond to oral 
corticosteroid with an increase in ventilatory function. A 7- 
day course of prednisolone, (20 mg. daily), normally results in 
a 30% increase in the patient's FEV 1 [Carmichael et al. 1981]. 
However, in 1981 Carmichael et al. noted the presence of a 
subpopulation of severe chronic asthmatics who did not improve 
their ventilatory function when given very high doses of oral 
corticosteroids ( up to 60 mg. of prednisolone 
daily)[Carmichael et al. 1981]. These patients were termed 
"corticosteroid resistant" (CR). The management of such 
patients poses a serious clinical problem since CR asthmatics 
may be disabled for long periods of time and may develope 
episodes of severe acute asthma which do not respond to 
conventional oral corticosteroid therapy. 
CR asthmatics show only three differences from 
Corticosteroid Sensitive (CS) asthmatics with respect to the 
clinical presentation of their disease. Firstly that CR asthma 
was of a longer duration than age and sex matched CS 
counterparts. The second difference was that a family history 
was significantly more common in the CR asthmatic patients. CR 
were also significantly more responsive to methacholine 
therapy than were CS asthmatics. A wide range of laboratory 
investigations was undertaken in an attempt to identify factors 
that might have been relevant to the response of asthma to 
corticosteroids, but with one exception these tests failed to 
discriminate between CR and CS asthma. The one exception was 
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the measurement of monocyte complement receptors (NCR) and of 
their enhancement (CRE) by a monocyte chemotactic factor 
(casein). This investigation showed that while the normal 
response to corticosteroids in CS asthmatics was a decrease in 
MCR and the degree of CRE, these changes were not observed in 
CR asthmatics, whose complement receptors were apparently 
uninfluenced by corticosteroid therapy [Kay et al. 1981]. No 
other studies have been performed in order to determine the 
markers and mechanism of corticosteroid resistance in asthma. 
The further study of corticosteroid resistant asthma is of 
importance in two respects. Firstly, CR asthmatics represent a 
serious clinical problem since they may be crippled by acute 
episodes of their disease and unnecessarily exposed to the 
hazardous side effects of systemic corticosteroid therapy. 
Recognition of CR asthma may therefore prevent the unnecessary 
exposure of these patient's to these drugs. Examination of CR 
asthma also offers the opportunity of elucidating the mechanism 
of action of corticosteroids in the commoner CS asthma. 
This thesis describes the in vitro and in vivo effects of 
the corticosteroid ,MPS , on leucocytes from CS asthmatics, CR 
asthmatics and controls. An assay of corticosteroid inhibition 
of colony formation by Mononuclear Cells (MNC) was used as an 
indicator of the in vitro sensitivity of monocyte and T -cell 
function to corticosteroid. Colony formation was seen to be a 
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sensitive indicator of both monocyte and T -cell function and 
was known to be responsive to inhibition by very low 
concentrations of corticosteroid [Krajewski and Wyllie 1981 
;Gordon et al. 1980]. The proportions of T -cell subsets, 
monocytes and Ia positive cells in the peripheral blood samples 
were determined using specific monoclonal antibodies as this was 
thought to effect colony formation [Filipovich 1982]. The 
colony cells were analysed likewise in order to determine 
whether low concentrations of MPS effect the proportions of 
cells of a given phenotype in the colonies. We also attempted 
to determine whether corticosteroid resistance was a property 
of monocytes alone or whether it was also present in T- cells. 
Finally, the haematological responses of CR and CS asthmatics 
to a single dose of prednisolone was also studied. 
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MATERIALS AND METHODS 
Selection of Patients and Controls: 
Four groups, each of 15 subjects were studied: Group 1 
were known Corticosteroid Resistant (CR) Asthmatics; Group 2 
were known Corticosteroid Sensitive (CS) Asthmatics; Group 3 
were new asthmatics of unknown corticosteroid sensitivity, but 
with asthma of sufficient severity to warrant a 7 -day course of 
systemic corticosteroid therapy; Group 4 were non -atopic 
controls. Essential preconditions to inclusion into the 
asthmatic groups were that the lowest recorded forced 
expiratory volume in one second (FEV1) was less than 60% of the 
predicted normal value and that there was a record of an 
increase in FEV1 of at least 30% following the use of a 
bronchodilator aerosol. No asthmatic included in this study had 
recieved systemic corticosteroid therapy during the month prior 
to admission. 
Corticosteroid resistance was defined as an increase FEV1 
of less than 15% following a seven day course of oral 
prednisolone (20 mg. or more daily).A patient was considered to 
be corticosteroid sensitive if their FEV1 had at least once 
increased by 30% or more during or at the end of a 7 day course 
of prednisolone [Carmichael et al. 1981]. 
Subjects were excluded from the study if there was 
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evidence of coexisting malignant disease, treatment with 
cytotoxic or immunosuppressive drugs, primary pituitary or 
adrenal gland dysfunction and intercurrent illness e.g. 
influenza and oral candidiasis. 
Preliminary Documentation and Clinical Tests: 
Age, sex, drug history and intercurrent illnesses were 
recorded for subjects in all groups. A total white blood cell 
count and differential white blood cell count was determined 
for all subjects. The best recorded FEV1 of the year was noted 
in patients with CR and CS asthma. The FEV1 and Peak Expiratory 
Flow Rate and endogenous plasma cortisol were measured in all 
asthmatic patients studied. A 50m1. sample of peripheral blood 
was withdrawn from each subject at 9.00 a.m.. A second 
peripheral blood sample was taken from new asthmatics at 9.00 
a.m. on the day following the administration of their last dose 
of corticosteroid. 
Preparation of Mononuclear cells from Peripheral Blood: 
Peripheral venous blood was withdrawn from each subject 
into a sterile bottle containing 2ml. of 2% EDTA in phosphate 
buffered saline. Mononuclear cells (MNC) were obtained from the 
peripheral blood by centrifugation over Ficoll -Hypaque and 
washed twice in Hank's medium. [Boyum 1968]. 
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Identification of Monocytes and T- Lymphocyte Sub- Populations 
in Peripheral Blood MNC. 
Subpopulations of T- lymphocytes, monocytes and Ia positive 
cells were quantified by means of monoclonal antibodies that 
were claimed by their manufacturers to define the following 
subpopulations: 
OKT3 (Ortho -mune): greater than 95% peripheral blood 
T -cells (PBT cells). 
OKT4 (Ortho -mune): inducer T -cell subset (65% of PBT 
T- cells). 
OKT8 (Ortho- mune): cytotoxic /suppressor T -cell subset 
(35% of PBT cells). 
OKM1 (Ortho- mune): peripheral blood monocytes (78% of 
adherent MNC and 18% of nonadherent MNC). 
Ia 231: MNC bearing Ia antigens (90% of B- Lymphocytes 
and monocytes; 20% of null cells and activated T- 
lymphocytes). 
Cells positive for OKT3, OKT4, OKT8, OKM1 or Ia231 were 
detected by indirect immunofluorescence with each of these 
monoclonal antibodies using fluorescein- isothiocyanate 
labelled Goat anti -mouse gamma immunoglobulin (GAM IgG) as the 
second antibody. 200 cells were counted with a fluorescent 
microscope under phase contast and fluorescence and the 
percentage of cells with membrane fluorescence was calculated. 
A control was included in each case that contained cells to 
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which only GAM IgG had been added. 
Colony Formation by Peripheral Blood MNC 
MNC from each subject were cultured in the absence of 
knowledge of the clinical data on the subject's corticosteroid 
sensitivity. The cells were suspended in RPMI 1640 supplemented 
with 10% heterologous serum with agar added to 0.3 %. Forty 
microlitres of this suspension (2x105 cells) were plated 
onto an underlayer of 0.2 ml. of 0.5% agar, 10% heterologous AB 
serum (the same source of serum was used throughout) and 2Oug 
of PHA (Difco). Methylprednisolone sodium succinate (Upjohn) 
was added to underlayers to give a final concentration of 
between 10 -5M to 10 -9M. Control cultures were set up to 
which only PHA was added. All cultures were in 17mm diameter 
wells in Multiwell dishes (Linbro 76- 033 -05). Cultures were 
incubated at 37 °C in a fully humidified atmosphere of 5% 
CO2 in air [Goube de la Forest 1979; Krajewski and Wyllie 
1981]. 
Clusters (defined as aggregates of between 10 and 40 
cells) and colonies (defined as aggregates of more than about 
40 cells) were scored after five days of incubation. The number 
of colonies and clusters were determined for one central field 
per well using a phase contrast microscope at a magnification 
of x100. Nine wells were scored in this way for each 
concentration of MPS. Clusters and colonies were also counted 
and sized using a Tektronic (4050 series) Graphic Information 
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system. 
Cell Identification of Harvested Clusters and Colonies. 
After scoring, 300}1l of PBS was added to each well in the 
Linbro plate. The plate was then gently agitated for 3 minutes 
at 4° C. Phase contrast microscopy indicated that this 
procedure detached clusters and colonies from the agar only, 
single cells remained embedded. The supernatant containing 
colonies and clusters was removed from each well and refluxed 
to form suspensions of cells for immunophenotyping using the 
monoclonal antibodies OKT3, OKT4 and OKT8 as described above. 
In some cases cytospins and suspensions of intact clusters 
and colonies were also obtained for Non Specific Esterase (NSE) 
histochemistry [Pearse 1960] and staining with Giemsa. Intact 
colonies and clusters were also fixed in glutaraldehyde for 
electron microscopy. Immuno- phenotyping with monoclonal 
antibodies was also performed as described below. 
Single Fluorescent Monoclonal Antibody Staining was 
performed on harvested intact colonies and clusters using the 
monoclonal antibodies OKT3, OKT4, OKT8, la 231 and OKM1 as 
described above. Care was taken to maintain the integrity of 
the clusters and colonies during processing. Harvested cells 
stained by indirect immunofluorescence were examined with a 
fluorescent microscope under phase and green fluorescence. 
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Double immunofluoresence was also performed on intact 
colonies and clusters using fluorescein conjugated OKT4 and 
rhodamine conjugated OKT8 and vica versa. A suspension of 
clusters and colonies was first incubated with OKT4 and 
rhodamine conjugated GAM IgG as above. The suspension of 
clusters and colonies was then washed and the direct 
fluorescein conjugate of OKT8 (Ortho -mune) applied. Clusters 
and colonies were also treated with OKT8 and rhodamine 
conjugated GAM IgG followed by incubation with the direct 
fluorescein conjugate of OKT4 (Ortho -mune). 
Colonies and clusters stained by this technique were 
examined with a fluorescent microscope under phase contrast, 
green fluorescence and red fluorescence. 
Colony Formation by Combinations of MNC from Pairs of CS 
and CR Asthmatics 
MNC were obtained from pairs of CS and CR asthmatics as 
before. The clinical corticosteroid sensitivities of the 
members of each pair were not made known to the experimenter. 
Monocyte enriched MNC suspensions were prepared by lysing the T- 
cells with the monoclonal antibody OKT3 and complement. T -cell 
enriched suspensions were similarly prepared by lysis of the 
monocyte component of the MNC fraction with OKM1 and 
complement. 
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6x106 MNC were resuspended in 1001 of RPMI 1640. 30}íl 
of the monoclonal antibody OKT3 or OKM1 was added and the 
suspension was incubated at 20 °C for one hour. 150,0 of 
human AB serum (source of complement) and 25111 of RPMI 1640 was 
then added and the cell suspension was placed in a shaking 
waterbath at 37 °C. for one hour. The cells were then washed 
in 5m1. of medium and resuspended at 10x106 cells /ml. 
The purity of cell suspensions was determined with the 
monoclonal antibodies OKT3 and OKM1 in conjunction with 
fluorescein labelled GAM IgG as described above. 
The culture procedure as described above was then applied 
to the following MNC suspensions (106 cells /mi.). 
(a) MNC from the CS patient only. 
(b) MNC from the CR patient only. 
(c) Monocyte enriched MNC from the CS asthmatic (CSM). 
(d) Monocyte enriched MNC from the CR asthmatic (CRM). 
(e) T -Cell enriched ZINC from the CS asthmatic (CST). 
(f) T -Cell enriched MNC from the CR asthmatic (CRT). 
(g) 40% CSÌI and 60% CST. 
(h) 40% CRM and 60% CRT 
(i) 40% CSM and 60% CRT 
(j) 40% CRM and 60% CST 
All were cultured in the presence and absence of 10 -8M 
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MPS. In addition cells from (j) were cultured in the absence of 
PHA. As before cultures were incubated for five days. Clusters 
and colonies were sized and counted using the Tektronic 
Information system. 
Haematological Effects of Corticosteroids In Vivo. 
4 Controls, 10 CS and 10 CR asthmatics were admitted to 
this study . 30m1. of peripheral blood were withdrawn from each 
subject at 9.00 a.m.. A single 20 mg. dose of prednisolone 
(Upjohn) was then administered orally. Second and third 
peripheral blood sample were taken 6 and 24 hours thereafter. 
A total white blood cell count and differential white 
blood cell count were performed on each blood sample. iIIIC 
suspensions were prepared as before. Subpopulations of T- 
cells, monocytes and Ia positive cells were quantified by 
indirect immuno- fluorescence with monoclonal antibodies. 
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RESULTS 
Clinical Observations: 
There was no significant difference between controls, CS 
and CR asthmatics with respect to age and sex ratio. There was 
also no significant difference between the CS and CR asthmatics 
in respect of the severity of their asthma on admission (as 
measured by their FEV1) and their plasma cortisol levels (Table 
1). CS and CR asthmatics did not differ significantly in the 
number of patients with intercurrent illnesses. However, CS and 
CR asthmatics did differ significantly with respect to the 
number in each group taking drugs in addition to those 
administered as part of maintenance therapy for their chronic 
asthma (Table 2). 
Phenotype of Leucocytes in the Peripheral Blood of 
Controls and Asthmatic Patients: 
Analysis of the peripheral blood revealed that there were 
few differences between the two asthmatic groups and between 
the asthmatic patients and controls. As expected the asthmatic 
patients had an eosinophilia not found in controls (Table 3). 
The CS asthmatics differed in several respects from the control 
group. CS asthmatics had fewer monocytes and T- inducer cells 
than controls. A higher proportion of T -cells of the CS 
asthmatics were of the suppressor /cytotoxic type and 
consequently the ratio of T- inducer cells to T- 

























































































































































































































































































































































































































































































































































Table 2 : Clinical Findings in Patients with CS and CR Asthma. 
PATIENT 
. & 
DRUGS INTERCURRENT ILLNESSES 
STEROID SENSITIVE 
ASTHMATICS 
1 . D.Mu - - 
2. S. Mo - - 
3. J.Mc - Diverticular disease 
4. A.Tu - - 
5. R. Pa - - 
6. S_ Vi - - 
7. J.Ga - - 
8. G_Cu - - 
9. G.Mc Tagamet Dyspepsia 
lO. G. Ni - Diabetic 
11.S.Wh - - 
12. R. Di - - 
13.S.Mu - - 
14.W.Cu - - 
15. W. Ba - - 
STEROID RESISTANT 
ASTHMATICS 
1. A.Br - - 
2. I . Ca Bel erg_ al Diverticular disease 
3. D.Ho - - 
4. C.Mc Zantac,ranitidine 
. Lasi x /slow}: - 
5. R. Da Pi ri ton - 
6. G. Go - - 
7. A.Wa Ampicillin Sore throat 
9. D.Ne Slow Trasicor - 
Aspirin 
9. J.Co Ampicillin/Ponstan - 
10. A. Gr Al l opuri nol /Lasi x 
Slow k: / Euhypnos - 
11.A.We Neonaclex /Septrin - 
12.J.Th Tagamet Mild angina 
13.J.Ma - - - 
14. J. Mo Frusemide/slow K 
Nifedipine /GTN - 
15.N.Hu - - 
"DRUGS" includes medications other than aerosol bronchodilators and 
inhalant corticosteroids. Significantly more drugs had been 
prescribed for patients with CR as compared with 
patients with CS asthma. 
(p = less than 0.02; Chi-squared test) 
"INTERCURRENT ILLNESSES" are those illnesses other than asthma that 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































suppressor /cytotoxic cells was reduced (Figure 1). The CR 
asthmatics resembled the controls in these respects (Tables 3 
and 4). 
MNC from CS asthmatics differed significantly in only one 
respect from MNC cells from CR asthmatics. CS asthmatics were 
shown to have a significantly reduced number, but not 
proportion, of T- inducer cells in their peripheral blood in 
comparison with CR asthmatics (tables 3 and 4). 
Colony Formation by MNC from Controls and Asthmatic 
Patients. 
In the presence of PHA, MNC from controls and asthmatics 
generated both colonies and clusters of cells in soft agar 
after 3 to 5 days incubation. Similar numbers of colonies were 
obtained from cultures of MNC from controls and asthmatics in 
the absence of MPS, representing a plating efficiency of 
approximately 0.05% (Table 5). The numbers of clusters formed 
was also similar for the three groups (data not shown). 
The number of colonies formed by MNC from Controls and CS 
asthmatics was shown to be significantly more sensitive to 
inhibition by 10 -8 U MPS than was colony formation by MNC 
from CR asthmatics (Table 5). The number of colonies that 
developed in the absence of MPS was denoted as 100% in order to 
minimise the purely technical variation in the plating 
efficiency between experiments (Figure 2). The concentration of 















































































































































































































































































































































































































































































































































































































































































































































































































































RATIO OF OKT4 +VE.(INDUCER) T -CELLS TO OKT8 +VE 
(SUPPRESSOR /CYTOTOXIC) T -CELLS IN THE PERIPHERAL 
































# : p = less than 0.01 













































































































































































































































































































































































































































































































































































































































COLONY FORMATION BY MNC FROM CONTROLS 
CS AND CR ASTHMATICS IN THE PRESENCE 





COLONIES AT 110 
10'-8M MPS 
i AS PERCENT 100 
OF NUMBER 
OF COLONIES 





































* : p = not significant (Two Sample t Test) 
x . p = less than 0.0001( " ) 
# : p = 1 ess than 0.0001( " " ) 
MPS causing a 50% decrease in the number of colonies formed was 
found to be 1.03 x 10 -9I1 for MNC from CS asthmatics as 
compared with 1.4 x 10 -8ii for MNC from CR asthmatics 
(Figure 3). 
The use of the Tektronic Information system allowed the 
detection of a significant difference between CS and CR 
asthmatics in the sensitivity of the number and size of 
clusters and colonies to the inhibitory effect of 10 -8 M 
MPS (Figure 4). 
The in vitro sensitivity of MNC from CS and CR asthmatics 
to the inhibitory effect of 10 -8M MPS on PHA- induced 
colony formation was not affected by a 7 -day in vivo course of 
oral MPS. Nor was a patient's sensitivity to the in vitro 
effects of MPS altered over time as demonstrated by 3 repeat 
samples. These effects were demonstrated using the Tektronic 
Information System (data not shown). 
The in vitro assay of corticosteroid sensitivity was 
of predictive value in the 6 "new asthmatic" cases studied. The 
MNC from 4 new asthmatics were found to be sensitive to the in 
vitro effect of MPS. These asthmatics subsequently responded 
well to a 7 -day course of systemic prednisolone with an 
improvement in their FEV1 of greater than 30 %. The MNC from 2 
asthmatics were found to be resistant to the inhibitory effect 
of MPS in vitro and it was correspondingly found that their 
FEV1 had not improved by more than 5% following a 7 -day course 














































































































































































































































































































































































































































































































































































































































































































































































































































































































of prednisolone therapy. We were therefore able to discriminate 
between CS and CR asthmatics on the basis of this assay of 
corticosteroid inhibition of colony formation by MNC (Table 6). 
The Cellular Components of Clusters and Colonies: 
Giemsa staining of cytospins of intact clusters and 
colonies revealed that they were composed predominantly of 
lymphoblasts and mature lymphocytes. Mitotic figures and 
degenerate cells were present in each colony as well (Plate 
1). One or two NSE positive cells with vacuolated cytoplasm and 
large cleaved nuclei were present in 95% of colonies and 
clusters examined and were thought to be monocytes (Plates 2 
and 3). Electron microscopy of intact colonies confirmed the 
light microscopic findings of lymphoblasts, mature lymphocytes 
and degenerate cells in the colony (Plate 4). Close apposition 
between colony cells was also noted (Plates 5 and 6). 
The presence of T -cells (Plate 7), monocytes (Plate 8), Ia 
positive cells (Plate 9), T- inducer cells (Plates l0a and 10b) 
and T- cytotoxic /suppressor cells (Plates lla and lib) in 
colonies were demonstrated using indirect immunofluorescence. 
The presence of T- inducer and T- cytotoxic /suppressor cells in 
the same colony was demonstrated in the majority of colonies 
examined using the double immunofluorescence method (Plates 12a 
and 12b). 
- 27 - 
Table 6 : Colony Formation by MNC from New Asthmatics 
in the Presence of 10 " -8M MPS Before and After a 7 -day 











or CR Asthma 
I . Ca 66 87 CR 
A. Mc 48 26 CS 
L. Do 40 29 CS 
A_ Si 25 19 CS 
W . Cu 98 81 CR 
S _ Mo .2.5 48 CS 
: Colonies ('1_) = Number of colonies formed 
in the presence of 10' -8M MPS as a 
percentage of the number of colonies 
formed in the absence of corticosteroid. 
C : See definitions of New Asthmatic, CS and CR asthma 
(Materials and Methods) 
PLATE 1: Cytospins of Colonies Stained with Giemsa. Mature 
Lymphocytes (m), Lymphoblasts (L), Mitotic Figures (MF) 
and Macrophages (Mp) are present in the colony. 
Magnification: x200 
PLATES 2 and 3: Cytospins of Colonies Stained for Non -Specific 
Esterase (NSE). A single NSE positive cell, thought to 
be a macrophage, is present at the centre of each colony (M). 
The central macrophage is surrounded by NSE negative T -cells 
(T). 
Magnification: x200 
PLATE L: Electron Micrograph of an Intact Colony. Cells showing 
the ultrastructural characteristics of lymphoblasts (L) 
and a monocyte (M) are present in the colony. 
Magnification: x12,000 
PLATTE 5: Electron Micrograph Showing Apposition between Colony Cells. 
Magnification: x20,000 
PLATE 6: Electron Micrograph Showing Gap Junction-like Structure 
Between Colony Cells (G) 
Magnification: x28,000 
PLATE 7: Cytospin of Colony Stained with Fluorescein Labelled 
OKT3 (a pan T -cell marker). The majority of the cells 
in the colony show membrane fluorescence. 
Magnification: x300 
PLATE 8: Cytospin of Colony Stained with Fluorescein Labelled 
OKM1 (a monocyte marker). The cell at the centre of the 
colony shows membrane fluorescence. 
Magnification: x600 
PLATE 9: Cytospin of Cluster of Cells Stained with Fluorescein 
Labelled la 231. The cells at the centre of the 
cluster show membrane fluorescence. 
Magnification: x600 
PLATE 10a: Colonies as viewed under the Phase Contrast Microscope. 
Magnification: x300 
PLATE 10b: The Same Colonies Stained with Fluorescein Labelled 
OKTL (a T- inducer cell marker). Numerous cells show 
membrane fluorescence. 
Magnification: x300 
PLATE lla: Cytospin of Colony Stained with Fluorescein Labelled 
OK'P8 (a T- cytotoxic /suppressor cell marker). A single 
cell in the colony shows membrane fluorescence (Ts). 
There is also an area of non -specific fluorescence (N). 
Magnification: x300 
PLATE lib: Cytospin of Clusters Stained as in Plate lla. A minority 
of cells in each cluster show membrane fluorescence. 
Magnification: x300 
PLATE 12a: Large Colony as viewed under the Phase Contrast 
Microscope. 
Magnification: x300 
PLATE 12b: The Same Colony Stained with Rhodamine Labelled 
OKTI4 and Fluorescein Labelled OKT8. The majority 
of cells in the colony are OKTL. positive (Ti). 
A small minority of cells are OKT8 positive (Ts). 
Magnification: x300 
Phenotype of T -cells Recovered From Harvested 
Clusters and Colonies: 
The phenotype of T -cells in suspensions of cells recovered 
from harvested colonies and clusters grown in the presence and 
abscence of 10 -8M MPS was determined. The proportion of T- 
cells, as defined by OKT3, was the same for recovered cells 
from cultures of MNC from CS and CR asthmatics in the presence 
and absence of MPS. The phenotype of T -cells (as defined by 
OKT4 or OKT8) which were obtained from colonies and clusters 
grown in the absence of MPS resembled that of the input cells 
(Tables 4 and 7). 
The most striking differences were obtained from clusters 
and colonies grown in the presence of 10 -8M MPS. 
Corticosteroid treated colonies and clusters from CS asthmatics 
differed significantly from those colonies and clusters that 
were generated in the absence of corticosteroid. It was shown 
that the proportion of T- inducer cells in clusters and 
colonies was significantly reduced by exposure to MPS. 
In contrast, the proportions of T- inducer and T- 
cytotoxic/suppressor cells in the colonies and clusters from CR 
asthmatics were not altered by the presence of MPS in the 
culture medium (Table 7). 





























































































































































































































































































































































































































































































































































































































































































Colony Formation by Combinations of Mononuclear 
Cells from Pairs of CS Asthmatics and CR asthmatics: 
Treatment of MNC suspensions from CS and CR asthmatics 
with the appropriate monoclonal antibodies (OKT3 or OKM1) and 
complement removed about 75% of T -cells and 50% of monocytes 
(Table 8). In this way it was possible to prepare suspensions 
of MNC that were substantially enriched with T -cells (CST and 
CRT) or with monocytes (CSM and CRM). 
CST, CSM, CRT and CRM all showed very poor colony 
formation in response to PHA when cultured alone. Furthermore 
no colony growth occurred in these cultures in the presence of 
10 -8M MPS. When CST was recombined with CSM normal PHA- 
induced colony formation was seen. The CSM /CST recombation was 
highly sensitive to inhibition of colony formation by 10 -8M 
MPS..The recombination of CRT and CRM resulted in normal PHA 
induced colony formation that was not inhibited by 10 -8M 
MPS (Table 9). 
When CSM was cultured with CRT, colony formation was 
highly sensitive to inhibition by 10 -8M MPS. In contrast 
when CRM was co- cultured with CST colony formation was highly 
resistant to inhibition by the same dose of corticosteroid 
(Table 9). This effect was demonstrated using the Tektronic 
Information system (Figure 5). No colony formation or "mixed 
leucocyte" type reaction occurred in these cultures in the 
- 29 - 
Table 8 : Preparation of Monocyte and T -cell depleted Cell Suspensions 
from MNC Derived from Pairs of CS and CR Asthmatics. 
of cells of phenotype shown 
OKT3 OKT3 OKM1 OEM 1 
before after before after 































The results of three experiments are shown in the table. 
Table 9 : NUMBER OF COLONIES FORMED BY COMBINATIONS OF 
MNC FROM A CS ASTHMATIC AND A CR ASTHMATIC 
IN THE PRESENCE AND ABSENCE OF STEROID. 
No 
Steroid + 1O" -8M MPS 
CS monocytes (CSM) 2 0 
CR monocytes (CRM) 2 0 
CS T -cells (CST) 0 2 
CR T -cells (CRT) 4 0 
CSM + CST 20 0 
CRM + CRT 30 24 
CSM + CRT 18 0 
CRM + CST 32 22 
CRM + CST without PHA 0 0_ 
CS : Corticosteroid sensitive 





























































































































































































































































































































































































































































































































































































































absence of PHA (Table 9). 
Haematological Responses to Corticosteroids In Vivo 
There were few differences between Controls and asthmatic 
patients in their haematological response to a single dose of 
prednisolone. Both CS and CR asthmatics developed a 
monocytopaenia and lymphopaenia within 6 hours (Figures 6 and 
7). In addition asthmatics from both groups and controls 
demonstrated a preferential depletion of T- inducer cells as 
compared to T- cytotoxic /suppressor cells within 6 hours of the 
administration of the drug (Figure 8). 
All but 1 of 10 CS asthmatics and all controls developed a 
marked neutrophilia and eosinopaenia within 6 hours of the 
administration of the drug, as expected. This single CS 
asthmatic failed to show a neutrophilia in response to 
corticosteroid. However eosinopaenia failed to develop in 4 of 
the 10 CR asthmatics and no neutrophilia developed in 5 CR 
asthmatics withih 6 hours of the administration of the 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Corticosteroid resistant asthma became a clinically 
recognised entity in 1981 when Grant and his coworkers noted 
that a small proportion of chronic asthmatics showed no 
response to systemic treatment with corticosteroids [Carmichael 
et al. 1981]. Subsequent study of the clinical characteristics 
of CR asthma revealed few differences between these asthmatics 
and the majority of CS chronic asthmatics. All but three of a 
wide range of relevant investigations failed to discriminate 
between CS and CR asthmatics. Most importantly CR asthmatics 
failed to improve their ventilatory function following a 7 -day 
course of systemic corticosteroid therapy. CR asthmatics were 
found to be more responsive to methacholine than were CS 
asthmatics. In addition monocyte complement expression (11CR) in 
CR asthmatics was less sensitive to inhibition by in vivo 
corticosteroid than was NCR expression by monocytes from CS 
asthmatics. 
In the experiments reported in this thesis it was found 
that CS asthmatics were significantly more sensitive than were 
CR asthmatics to the inhibitory effect of corticosteroid on PliA- 
induced colony formation in vitro. This difference in 
sensitivity to corticosteroid was constant over time and was 
unaffected by a 7 -day course of systemic corticosteroid 
therapy. The in vitro assay of corticosteroid sensitivity was 
also found to be of predictive value in six "new asthmatic" 
cases. 
- 31 - 
The difference in the corticosteroid sensitivities of MNC 
from CS and CR asthmatics in vitro was not absolute. CR 
asthmatics differed from CS asthmatics with respect to the 
range of concentrations of corticosteroid that caused 
inhibition of colony formation. Colony formation by MNC from 
both groups of asthmatics was always totally inhibited by 
10 -5M MPS. The maximal difference in corticosteroid 
sensitivity occured at 10 -8M MPS which represents a 
concentration of corticosteroid which would saturate the high 
affinity cytoplasmic glucocorticoid receptors described in many 
cell types. This concentration is also above the normal 
physiological range of cortisol. In addition, the non -parallel 
dose response curves of CS and CR asthmatics indicated that the 
difference between the l'INC of these two groups of asthmatics 
was not simply a manifestation of a difference in the number of 
receptors for corticosteroid per responsive cell. 
The CS asthmatics studied were matched to CR asthmatics 
with respect to age range, sex ratio, endogenous plasma 
cortisol and the severity of their asthma on admission to the 
study. Therefore the difference between the in vitro 
sensitivities of MNC from CR and CS asthmatics could not be 
explained on the basis of a difference in these clinical 
characteristics of the two groups of asthmatics. The 
proportions of monocytes, T- inducer cells and T- suppressor 
cells in the tINC fraction have been reported to have effects on 
the outcome of mitogen induced T -cell proliferation in vitro 
- 32 - 
[Gordon et al. 1980; Filipovich 1982]. As there was no 
significant difference between the MIN fractions from CS and CR 
asthmatics in these respects, however, the difference in 
steroid responsiveness of colony growth in vitro could not be 
attributed to such effects. 
There is much evidence that monocytes are responsible for 
the initiation PHA- induced T -cell colony formation and that 
this function of monocytes is corticosteroid sensitive. It was 
demonstrated that the majority of colonies were centred on a 
single monocyte. It is also known that monocytes release IL 1 
on stimulation by PHA and thereby initiate the proliferation of 
T -cells as described above. Monocyte production of IL 1 is 
inhibited by low concentrations of corticosteroid and 
inhibition of colony formation by these drugs is thought to be 
a manifestation of this [Krajewski and Wyllie 1981 ; Snyder and 
Unanue 1982]. The presence of CR monocytes was demonstrated by 
culturing combinations of MNC from pairs of CS and CR - 
asthmatics. The combination of monocytes from a CR asthmatic 
with T -cells from a CS asthmatic resulted in colony growth 
which was resistant to 10 -8ìi MPS, whereas the combination 
of monocytes from a CS asthmatic with T -cells from a CR 
asthmatic resulted in corticosteroid inhibited colony growth.It 
therefore propose that corticosteroids fail to inhibit IL 1 
production by monocytes from CR asthmatics. 
Defects in corticosteroid responsiveness may also be 
present in leucocytes other than monocytes from CR asthmatics. 
- 33 - 
There is evidence that eosinophils, polymorphs and T- 
lymphocytes of CR asthmatics differ from those of CS asthmatics 
in response to corticosteroid. The investigation of the 
haematological effects of a single dose of prednisolone 
demonstrated that all but one of the 4 controls and 10 CS 
asthmatics developed an eosinopaenia and a neutrophilia within 
6 hours of the administration of the drug, whereas 6 of the 10 
CR asthmatics did not show any change in the numbers of 
circulating eosinophils and /or neutrophils in response to the 
corticosteroid. 
Study of the clinical records showed that the CS and CR 
asthmatics studied in this thesis had received a similar 
quantity of systemic corticosteroid during the year prior to 
admission to this study (Dr. Ian Grant, personal 
communication). Although as stated earlier patients from 
neither group had received such therapy during the month prior 
to their admission to the project. It has been shown that 
patients who receive chronic systemic corticosteroid therapy 
for asthma and graft versus host disease have significantly 
reduced numbers of T- inducer cells in their peripheral blood as 
compared with untreated age and sex matched untreated controls 
[Moll et al. 1982 and Haynes and Fauci 1978]. The CS asthmatics 
studied in this thesis were also shown to have significantly 
reduced numbers of T- inducer cells in their peripheral blood as 
compared with controls. T- inducer cell numbers were not reduced 
in CR asthmatics hence it is possible that CR asthmatics do not 
show this presumptive effect of chronic systemic corticosteroid 
- 34 - 
therapy. 
It was shown that the lymphocytes recovered from colonies 
and clusters which did develop from the MNC of CS asthmatics in 
the presence of 10 -8M MPS were substantially depleted in T- 
inducer cells as compared to those clusters and colonies that 
were not exposed to MPS. In contrast the proportion of T- 
inducer cells in colonies and clusters generated by MNC from CR 
asthmatics was unaffected by the presence of MPS in the culture 
medium at the same concentration. 
On the basis of this evidence it seems possible that 
corticosteroid resistance may be expressed by cells other than 
monocytes from patients with CR asthma. It is concievable that 
the responses of granulocytes and T- lymphocytes are themselves 
dependent on monocyte function. This question could be answered 
by direct experiments on the corticosteroid sensitivity of 
these granulocytes and T- cells. Thus neutrophil sensitivity to 
corticosteroid could be tested by an assay of induced 
lipomodulin production; eosinophil complement receptor 
enhancement following chemotactic stimuli could be compared in 
the presence and absence of corticosteroid ;and production of 
IL 2 by purified T- cells, stimulated in the absence of 
monocytes by IL 1 containing supernatants could be used as a 
test of the corticosteroid sensitivity of these cells. 
- 35 - 
The simplest interpretation of the data, however, is that 
the monocyte defect demonstrated in vitro in cells from CR 
asthmatics, is responsible for the corticosteroid resistance of 
their disease in vivo. This would therefore imply that the 
monocyte is the principle target of the therapeutic action of 
corticosteroids in CS asthma in vivo. 
There are several ways in which the therapeutic action of 
corticosteroid in CS asthma might be mediated by monocytes and 
these fall into two main categories: a direct action involving 
effects of monocyte products on the synthesis of inflammatory 
mediators by mast cells and the indirect action of monocyte 
products on immunoregulatory cells causing the suppression of 
IgE production by plasma cells [Hirata 1982; Uede et al. 1983]. 
The assay used in this thesis has stressed the indirect action 
of corticosteroids. We would infer from the results that IL 1 
production by CR monocytes is not inhibited by low 
concentrations of corticosteroid. This might result in the 
continued promotion of production of IgE in vivo. However 
pharmacologic doses of corticosteroid reduce the serum level of 
IgG but causes an increase in total serum IgE and specific IgE 
in vivo [Posey et al. 1978]. 
It therefore seems more likely that the specific defect 
that we have detected in monocytes from CR asthmatics in vitro 
is a manifestation of a general defect in the corticosteroid 
responsiveness of monocytes from these patients. This is 
supported by the data of Kay et al. on monocyte complement 
- 36 - 
receptor enhancement, which represents a different endpoint of 
monocyte function and which was found to be insensitive to 
modulation by corticosteroids in CR asthmatics [Kay et al. 
1981]. Further study of corticosteroid sensitive functions 
of monocytes which are of greater relevance to the direct 
action of these drugs in asthma in vivo are required. This 
would undoubtedly include an assay of lipomodulin 
production by monocytes from CS and CR asthmatics. 
In this thesis it has been demonstrated that monocyte 
function in CR asthmatics is insensitive to corticosteroid. The 
monocyte defect in CR asthma may be genetic or acquired. 
Interestingly there is a higher association of CR asthma with a 
family history of atopy than with CS asthma. Consequently a 
genetic basis for corticosteroid resistance was considered and 
HLA studies of patients with the condition have been initiated 
[Carmichael et al. 1981]. 
Recent work on the effects of corticosteroids on T -cell 
lines indicate that the origin of corticosteroid resistance may 
be a genetically determined defect in the corticosteroid 
receptor pathway or an epigenetic defect arising during a 
process such as differentiation [Gas son and Bourgeois 1983]. In 
addition Goodwin has shown that the MNC from elderly healthy 
subjects (over 65 years of age) are more resistant to the 
effects of corticosteroid in vitro than are MNC from young 
- 37 - 
healthy controls [Goodwin 1982]. The relevance of these 
findings to CR asthma may be determined in the future. 
Corticosteroid resistance has been demonstrated in a small 
proportion of chronic asthmatics in Edinburgh. However the 
implications of this condition are much wider. There is no 
reason to suppose that corticosteroid resistance does not occur 
in the general population. In this case corticosteroid 
resistance would be of importance when the response to these 
hormones was essential for the success of medical therapy, as 
in Asthma, Sarcoidosis, Graft versus Host disease, Systemic 
Lupus Eyrthematosus and Rheumatoid Arthritis. Furthermore it is 
interesting to inquire whether a monocyte defect of the type 
described here would affect the responses of the immune system 
to modulation by physiological concentrations of corticosteroid 
and perhaps influence the course of chronic inflammatory 
disorders. Further investigation of the biology of 
corticosteroid resistance in asthma may therefore have 
implications for other developmental and pathological 
processes. 
- 38 - 
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1 
SUMMARY 
1. In order to investigate the cellular mechanism of 
glucocorticoid resistance in chronic asthma, peripheral blood 
mononuclear cells from asthmatic patients were cultured in soft 
agar. 
2. Cells from patients known to be clinically sensitive to 
glucocorticoid therapy did not differ significantly from those 
from clinically resistant patients in terms of their immuno- 
phenotype or the number of colonies generated by culture in the 
presence of phytohaemagglutinin. 
3. The glucocorticoid methylprednisolone at low concen- 
tration (10 nmol /1) inhibited colony growth from cells of 
glucocorticoid sensitive patients, whereas there was much less 
inhibition of colony growth from resistant patients' cells. 
4. In a small prospective study inhibition of colony growth 
by methylprednisolone in vitro correlated with the subsequently 
determined sensitivity of the patients' asthma to glucocorticoid 
therapy. 
5. Assessment in vitro of glucocorticoid sensitivity may 
help to predict which patients may be spared ineffectual gluco- 
corticoid medication.The results raise the possibility that 
peripheral blood mononuclear cells may respond to glucocorticoid 




Some patients with chronic asthma are resistant to systemic 
treatment with glucocorticoids, even in high dosage. Measure- 
ments of forced expiratory volume in one second (FEY1) show 
striking differences between the response of resistant and 
sensitive patients to the short -term administration of systemic 
glucocorticoids, in sharp contrast to the considerable increases 
recorded in both groups after use of a bronchodilator aerosol 
[1]. Detailed study of a large group of glucocorticoid 
resistant asthmatic patients in Edinburgh has already identified 
some differences in the aetiology and clinical patterns of asthma 
between the two groups. It was considered improbable, however, 
that these differences were central to the phenomenon of 
glucocorticoid resistance. Only one of a wide range of 
laboratory investigations discriminated between resistant and 
sensitive asthmatic patients - the measurement of monocyte 
complement receptors and their enhancement by Casein, a monocyte 
chemotactic factor [2]. In this paper we show that peripheral 
blood mononuclear cells (MNC) from glucocorticoid resistant 
asthmatic patients are relatively unresponsive to glucocorticoid 
,fin vitro and we suggest that this may be used to predict 
glucocorticoid resistance in asthmatic subjects whose clinical 
response to these drugs has not yet been assessed. 
3 
PATIENTS AND METHODS 
The laboratory studies reported in this paper were performed 
on venous blood samples obtained from 41 patients with chronic 
asthma and 15 normal subjects (Table 1). 
All 41 asthmatic patients had been shown to respond to the 
inhalation of an aqueous 62- agonist aerosol (salbutamol, 5 mg) by 
an increase in the FEV1 of at least 30% from the base -line figure 
of less than 60% of the predicted normal value. This evidence of 
reversible airflow limitation was regarded as consistent with the 
diagnosis of asthma. The patients were, however, selected in 
such as way as to form three separate groups. 
.róu,P_1 consisted of 15 asthmatic patients who were 
'glucocorticoid resistant' in that their FEV1 did not increase by 
more than 15% after a short course of prednisolone by mouth, 
even when the dose was increased progressively to at least 60 
(and in some cases to 1000) mg /day. Although 9 were on regular 
treatment with a glucocorticoid aerosol, the mean FEV1 for the 
whole group was no higher on the day of blood sampling than on 
earlier clinic visits. 
arou2_2. consisted of 15 asthmatic patients who were 
'glucocorticoid sensitive', as shown by an increase in FEV1 of 
more than 30% after a 7 -day course of prednisolone in a dose of 
only 20 mg /day. Nine of these patients had recently started 
regular treatment with a glucocorticoid aerosol and in all 15 the 
disease was well controlled at the time of blood sampling. This 
4 
may explain why the mean FEV1 was significantly higher at that 
time than at their initial clinic visit. 
Group 1 consisted of 11 'new' asthmatic patients whose response 
to prednisolone, in terms of FEV1, had not previously been 
assessed. 
As observed in the original study [1], the glucocorticoid 
resistant patients were on average older, had a longer history of 
asthma, and were more prone to nocturnal wheeze and 'morning 
dipping' than the sensitive patients. There was no difference 
between the two groups in respect of atopic status or smoking 
habits. The more frequent family history of asthma in the 
resistant patients noted in the original study [1] did not emerge 
in the smaller numbers included in the present series (Table 1). 
The criteria for inclusion of patients in groups 1 and 2 
eliminated all asthmatic patients whose FEV1 response to 
glucocorticgid was in the 'grey area' between 15 and 30 %, with 
the result that only patients who were unequivocally either 
'glucocorticoid resistant' or 'glucocorticoid sensitive' were 
studied. Although this facilitated correlation of clinical and 
laboratory findings, it left unexplored the possibility that 
'glucocorticoid resistance' and 'glucocorticoid sensitivity' 
might represent the ends of a continuous spectrum. It was hoped 
that the inclusion of group 3'would elucidate this point. The 11 
patients in that group were asthmatics who had presented with 
moderately severe airflow obstruction for which a course of oral 
prednisolone was indicated. Their FEV1 was measured before, and 
5 
immediately after, a 7 -day course of prednisolone (20 mg /day). 
Laboratory studies were undertaken in all 11 cases before 
treatment commenced and again in 9 on its completion. 
None of the asthmatic patients or the controls had co- 
existing malignant disease, was being treated with cytotoxic or 
immunosuppressive drugs, or was suffering from any form of inter - 
current infection, including oropharyngeal candidiasis. About 
half of the patients in groups 1 and 2 had previously been 
treated with oral prednisolone but there was no significant 
difference between the groups in terms of total dosage. For at 
least 4 weeks prior to this study no subject had received 
glucocorticoid therapy other than beclomethasone dipropionate by 
inhalation. The dose did not exceed 400 micrograms daily, which 
is known not to suppress pituitary -adrenal function [3]. On the 
morning of blood sampling the mean plasma cortisol was normal in 
all groups (Table 1). 
Analysis of Blood Samples: 
Peripheral venous blood (50 ml) was withdrawn at 09.00 hours 
from each subject into a sterile bottle containing 2m1 of 2% EDTA 
in phosphate buffered sodium chloride solution (154 nmol /1). All 
the laboratory studies were carried out without knowledge of the 
clinical status of the subjects. Total leucocyte count, 
differential leucocyte cell count and plasma cortisol were 
determined on all samples. 
Mononuclear cells (MNC) were obtained from the peripheral 
blood by centrifugation over Ficoll- Hypaque [4] and were then 
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washed twice in Hank's balanced salt solution. Subpopulations of 
T- lymphocytes, monocytes and Ia positive cells were quantified by 
means of monoclonal antibodies with the following specificities: 
OKT3 (peripheral blood T- cells); OKT4 (inducer T -cell subset); 
OKT8 (cytotoxic /suppressor T -cell subset); OKM1 (peripheral 
blood monocytes); and Ia231 (MNC bearing Ia antigens, including 
90% of B- lymphocytes and monocytes, 20% of null cells, and 
activated T- lymphocytes). Antibodies in the OK series were 
obtained from Ortho Diagnostics Ltd. 
Cells positive for OKT3, 0KT4, OKT8, OKM1 or Ia231 were 
detected by indirect immunofluorescence using fluorescein - 
isothiocyanate labelled goat anti -mouse immunoglobulin (Meloy 
Ltd) as the second antibody. The percentage of cells with 
membrane fluorescence was calculated from study of 200 cells. 
For each case a negative control was included: cells to which 
only second antibody had been added. 
Colony formation from peripheral blood mononuclear cells 
MNC from each subject were cultured by using previously 
described methods [5,6]. For each culture, 2 x 105 cells were 
suspended in 40 )l of RPMI 1640 supplemented with 10% 
heterologous serum and 0.3% agar, and plated on to an underlayer 
of 0.2ml of 0.5% agar containing 20)ßg of phytohaemagglutinin 
(Difco) and 10% heterologous ,AB serum (the same source of serum 
was used throughout). Methylprednisolone sodium succinate (MP; 
Upjohn) was added to underlayers to give a final concentration of 
10 nmol /1. Control cultures received no MP. All cultures were 
7 
in 17mm diameter wells in Multiwell dishes (Linbro) and were 
incubated at 37 °C in a fully humidified atmosphere of 5% CO2 in 
air. After 5 days of incubation colonies (defined as aggregates 
of more than 40 cells) were counted by phase contrast microscopy 
at x 100 magnification in three central fields in each of three 
replicate wells. This relatively simple scoring method has been 
verified by detailed computer- assisted analysis of the size 
distribution of all cell clusters in the cultures. Detailed 
immunophenotyping of these colony cells showed them to consist 
mainly of OKT4 and OKT8 lymphocytes, but most colonies also 
included a central cell bearing monocyte markers (M.C. Poznansky, 
A.C.H. Gordon, I.W.B. Grant and A.H. Wyllie, unpublished work). 
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RESULTS 
Analysis of the peripheral blood leucocytes revealed that 
there were few differences between the known 'glucocorticoid 
resistant' asthmatic patients (group 1) and the 'glucocorticoic 
sensitive' asthmatic patients (group 2) or between'the asthmatic 
patients and normal control subjects. As expected, the asthmatic 
patients had an eosinophilia not found in controls. The 
resistant and sensitive patients did not differ significantly 
from each other or from control subjects in terms of the 
proportion of T- cells, T- inducer cells, Ia positive cells or 
cells reacting with the OKM1 monocyte monoclonal antibody. There 
was a slightly higher proportion of T- suppressor /cytotoxic cells 
in the blood of sensitive asthmatic patients as compared with 
controls. The mean proportion of T- suppressor /cytotoxic cells in 
resistant asthmatic patients was less than in sensitive 
asthmatics, but this difference failed to attain significance at 
the p <0.05 level (Table 2). 
In the absence of MP, MNC from both controls and asthmatic 
patients in groups 1 and 2 generated similar numbers of colonies 
in soft agar after 3 -5 days incubation, representing a plating 
efficiency of approximately 0.05% (Table 3). Incubation during 
growth with MP at 10 nmol /1 significantly inhibited colony 
numbers developing from the MNC of control subjects and sensitive 
asthmatics. In contrast this concentration of MP had little 
effect on colony development from the MNC of resistant asthmatics 
(Table 3). 
9 
To minimize purely technical variations in the plating 
efficiency and in order to permit comparison between patients, 
the number of colonies developing from each patient's MNC in the 
presence of MP at 10 nmol /1 was expressed as a percentage of the 
number developing in its absence (Fig. 1). It was clear that the 
responses of individual patients, expressed in this way, fell 
with very few exceptions into two categories. Colony growth from 
MNC of glucocorticoid sensitive patients was strongly inhibited 
by MP jq vitro, whereas growth from MNC of resistant patients was 
affected little by MP. In all but one of the control subjects 
colony growth was inhibited by MP to the same extent as that from 
glucocorticoid sensitive asthmatic patients. 
The clinical sensitivity of the 11 asthmatic patients in 
group 3 to glucocorticoid was unknown at the outset of the study. 
In these patients, however, the response to glucocorticoid, as 
determined by colony inhibition j vitro, was found to correlate 
closely with the extent to which FEV1 increased during subsequent 
treatment with oral' prednisolone (Fig. 2). This is shown in 
Fig.2, where percentage changes in colony number, induced in 
vitro by MP, are plotted against the percentage change in FEV1 , 
resulting from a 7 -day course of oral prednisolone. An identical 
relationship was evident when the in vitro responses were plotted 
against the absolute change in FEV1 (data not shown). 
The percentage change in colony number, induced by MP in 
vitro, appeared to be characteristic for each subject. Thus, on 
retesting 6 subjects between 3 weeks and 4 months later, the 
divergence from the initial value was in every case less than 20% 
10 
(Fig. 3A). In particular, colony numbers from glucocorticoid 
sensitive patients and control subjects were strongly inhibited 
by MP on both occasions (i.e. to less than 60% of the untreated 
value). In glucocorticoid resistant patients colony numbers 
remained in excess of 60% of the untreated value. 
Perhaps surprisingly, glucocorticoid medication did not 
appear to affect the extent to which colony growth was inhibited 
by MP j,n vitro. Thus in the 10 subjects tested before and 
immediately after the 7 -day course of oral prednisolone, colony 




Previous studies of the characteristics of overtly glucocor- 
ticoid resistant asthmatic patients have revealed few differences 
from the majority of patients with chronic asthma, who respond 
well to glucocorticoids [1,2]. In this paper we- show that MNC 
from such glucocorticoid resistant patients were significantly 
more resistant to the effects of MP in vitro than the MNC from 
clinically sensitive asthmatic patients or normal controls. The 
criterion adopted was the ability of PHA -stimulated mononuclear 
cells to grow as colonies in soft agar. This phenomenon is known 
to depend upon interactions of monocytes and lymphocytes [6,7], 
but as the proportions of monocytes and T cells in the peripheral 
blood of the two groups of patients were similar, the observed 
difference in glucocorticoid responsiveness in vitro cannot be 
attributed merely to differences in the relative numbers of cell 
types under study. 
MNC from individual patients with c,learcut glucocorticoid 
resistant or sensitive asthma (i.e. groups 1 and 2) responded to 
MP in vitro in a consistent manner on repeated testing. The 
response bore no relationship to the endogenous plasma cortisol 
at the time of blood sampling (see Table 1). Further, the 
response in vitro did not change after a 7 -day course of systemic 
glucocorticoid therapy. Hence it is probable that the 
mononuclear cells of each individual have a characteristic 
response to glucocorticoid .n vitro, uninfluenced by endogenous 
cortisol or by the administration of exogenous glucocortfcoid. 
12 
The close correlation between the response to glucocorticoid 
in vitro and in vivo suggests that the cell types involved in 
generating colonies In vitro (i.e. monocytes and T lymphocytes) 
may be similar to those contributing to the pathogenesis of., 
asthma in these patients. A substantial body of evidence 
implicates cells of the monocyte lineage in the pathogenesis of 
asthma [8 -10]. There are several ways in which improvement in 
the clinical condition of asthmatic patients treated with 
glucocorticoids may depend upon the effects of these drugs on 
such cells. Of particular relevance to the interpretation of the, 
present results is the well documented inhibition of production 
of interleukin 1 (IL 1) by low concentrations of glucocorticoids 
[11 -13]. IL 1 is a monocyte product which mediates mitogen- 
induced T -cell proliferation in vitro [14], and is known to 
support T -cell colony formation in soft agar [7]. It is also a 
pyrogen and promotes the synthesis of inflammatory mediators from 
arachidonic acid [15,16]. Other effects of glucocorticoids that 
may be implicated in their therapeutic action in, asthma are 
modulation of complement receptor expression by monocytes [2] and 
induction in leucocytes of the phospholipase A2 inhibitor 
lipomodulin [ 17 ], which also suppresses reactions mediated by 
immunoglobulin E [18]. It thus may be postulated that cells of 
monocyte lineage within the lungs of glucocorticoid resistant 
asthmatic patients might continue to secrete inflammatory 
mediators, support lymphocyte proliferation, and exist in a 
hyperreactive state with enhanced complement receptor expression, 
despite the presence of inhibitory concentrations of 
glucocorticoids. 
13 
We embarked on this study on the premise that glucocorticoid 
resistance in chronic asthma was an all or none phenomenon, which 
is what prompted us to restrict our investigations in vitro 
initially to patients whose asthma was readily recognizable on 
clinical criteria as sensitive or resistant. It would seen, 
however, from the observations on previously untreated, and thus: 
unselected, asthmatic patients that sensitivity and resistance 
may form a continuous spectrum. At one end would be patients 
whose asthma is overtly resistant to systemic glucocorticoids, 
even in high dosage. It is important to recognize these patients 
since they may otherwise be needlessly exposed to hazardous side 
effects. This study indicates one way in which such patients may 
be identified. 
Although the cellular basis of glucocorticoid resistance 
remains obscure, our findings suggest that a defect in 
mononuclear cells, and perhaps monocytes in particular, may be 
responsible. We are currently defining the nature of this 
cellular defect more precisely. We are also exploring the 
potential of simpler tests in vitro to identify resistant 
patients before they are treated with glucocorticoids either for 
asthma or for other diseases normally responsive to these 
therapeutic agents. 
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IMMUNOPHENOTYPE OF PERIPHERAL BLOOD MONONUCLEAR CELLS OF 
ASTHMATIC PATIENTS AND CONTROLS 
Mean results ± SD are shown 










OKT3 45.1 46.2 47.2 
(±10.9) (±7.0) (±11.6) 
ORT4 27.2 26 .0 30.9 
( ±7.1) ( ±7.9) ( ±9.1) 
OKT8 17.8 21.6* 16.3* 
( ±5.5) ( ±6.3) ( ±4.7) 
Ia231 13.8 13.5 12.9 
( ±4.9) (±6.2) ( ±6.9) 
OKM1 29.0 26.7 29.3 
( ±7.4) ( ±10.0) ( ±9.4) 
# 
P < 0.01 (t-test) 
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TABLE 3 
EFFECT OF GLUCOCORTICOID ON COLONY FORMATION BY PERIPHERAL BLOOD 
MONONUCLEAR CELLS FROM ASTHMATIC PATIENTS AND CONTROLS 
The reduction in colony number with methylprednisolone.is significant 
for controls and sensitive asthmatic patients (P < 0.0001) but not for 












No glucocorticoid 35.3 (± 9.5) 38.3 ($ 6.6) 37.7 (± 5.2) 
Methylprednisolone 31.8 (± 12.8) 13.8 (± 7.3) 14.7 (± 8.8) 
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LEGENDS TO FIGURES 
Fig. 1. Effect of methylprednisolone on colony formation from 
mononuclear cells of resistant and sensitive 
asthmatic patients (Groups 1 and 2) and of controls. 
The number of colonies developing in the presence of 
MP at 10 nmol /1 is expressed as a percentage of the 
number which developed in the absence of MP, from 
cells of the same subject. Each point derives from 
a different subject. 
Fig. 2. Correlation between inhibition of colony growth by MP 
in vitro and relief of bronchospasm by a course of 
prednisolone in vivo, in the 11 unselected patients 
in group 3. The correlation is significant (P < 
0.005). 
Fig. 3. Repeated estimations of inhibition of colony growth 
by MP in vitro. In 3A the initial values (0) and 
values obtained on retesting under identical 
conditions (point of arrow) are shown for 6 subjects 
(2 of them glucocorticoid resistant). In 3B initial 
values (0) and values obtained immediately after a 7- 
day course of oral prednisolone (point of arrow) are 
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